Achievement of Different Treatment Targets with Izokibep in Psoriatic Arthritis at 16- and 46-Weeks

ACELYRIN, INC. is a Los Angeles area-based late-stage clinical biopharmaceutical company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.

To date, more than 300 patients – many for up to three years – have received izokibep, a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies. With high potency and small molecular size, izokibep can reach high drug exposure levels through a single, subcutaneous injection that monoclonal antibodies require IV administration to achieve. Additionally, the small size of izokibep – about one tenth the size of a monoclonal antibody – enables its potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies.